Breast lesions: Evaluation with dynamic contrast-enhanced T1-weighted MR imaging and with T2*-weighted first-pass perfusion MR imaging

Radiology

Volumn 216, Issue 2, 2000, Pages 545-553

  Kvistad, Kjell A ^a   Rydland, Jana ^a   Vainio, Jari ^a   Smethurst, Hanne B ^a   Lundgren, Steinar ^a   Fjøsne, Hans E ^a   Haraldseth, Olav ^a  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Breast neoplasms, diagnosis; Breast neoplasms, MR; Magnetic resonance (MR), perfusion study

Indexed keywords

GADODIAMIDE; GADOLINIUM;

ARTICLE; ASPIRATION BIOPSY; BREAST BIOPSY; BREAST LESION; CANCER GRADING; CONTRAST ENHANCEMENT; CONTROLLED STUDY; CYTOLOGY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DIAGNOSTIC VALUE; FEMALE; FIBROADENOMA; HUMAN; IMAGE QUALITY; MAJOR CLINICAL STUDY; MAMMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; TISSUE PERFUSION; TUMOR VOLUME;

EID: 0033876933     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiology.216.2.r00au36545     Document Type: Article

References (39)

1. Harms SE, Flamig DP, Evans WP, Harries SA, Bown S. MR imaging of the breast: current status and future potential. AJR Am J Roentgenol 1994; 163:1039-1047.
2. Friedrich M. MRI of the breast: state of the art. Eur Radiol 1998; 8:707-725.
3. Gilles R, Guinebretiere JM, Lucidarme O, et al. Nonpalpable breast tumors: diagnosis with contrast-enhanced subtraction dynamic MR imaging. Radiology 1994; 191:625-631.
4. Boetes C, Strijk SP, Holland R, Barentsz JO, van der Sluis RF, Ruijs JHJ. False-negative MR imaging of malignant breast tumors. Eur Radiol 1997; 7:1231-1234.
5. Bone B, Aspelin P, Bronge L, Isberg B, Perbeck L, Veress B. Sensitivity and speciticity of MR mammography with histopathological correlation in 250 breasts. Acta Radiol 1996; 37:208-213.
6. Fobben ES, Rubin CZ, Kalisher L, Dembner AG, Seltzer MH, Santoro E. Breast MR imaging with commercially available techniques: radiologic-pathologic correlation. Radiology 1995; 196:143-152.
7. Gilles R, Meunier M, Lucidarme O, et al. Clustered breast calcifications: evaluation by dynamic contrast-enhanced subtraction MRI. J Comput Assist Tomogr 1996; 20:9-14.
8. Harms SE, Flamig DP, Hesley KL, et al. MR imaging of the breast with rotating delivery of excitation off resonance: clinical experience with pathologic correlation. Radiology 1993; 187:493-501.
9. Muller-Schimpfle M, Stoll P, Stern W, Kurz S, Dammann F, Claussen CD. Do mammography, sonography, and MR mammography have a diagnostic benefit compared with mammography and sonography? AJR Am J Roentgenol 1997; 168:1323-1329.
10. Fischer U, Heyden D, Vosshenrich R, Vieweg I, Grabbe E. Signal/time relation of benign and malignant lesions in dynamic 2D-MR imaging of the breast. Fortschr Rontgenstr 1993; 158:287-292.
11. Fischer U, Kopka L, Brinck U, Korabiowska M, Schauer A, Grabbe E. Prognostic value of contrast-enhanced MR mammography in patients with breast cancer. Eur Radiol 1997; 7:1002-1005.
12. Heywang SH, Wolf A, Pruss E, Hilbertz T, Eiermann W, Permanetter W. MR imaging of the breast with Gd-DTPA: use and limitations. Radiology 1989; 171:95-103.
13. Piccoli CW. Contrast-enhanced breast MRI: factors affecting sensitivity and specificity. Eur Radiol 1997; 7:281-288.
14. Nunes LW, Schnall MD, Orel SG, et al. Breast MR imaging: interpretation model. Radiology 1999; 202:833-841.
15. Soderstrom CE, Harms SE, Copit DS, et al. Three-dimensional RODEO breast MR imaging of lesions containing ductal carcinoma in situ. Radiology 1996; 201:427-432.
16. Orel SG. High-resolution MR imaging for the detection, diagnosis, and staging of breast cancer. RadioGraphics 1998; 18:903-912.
17. Mussurakis S, Gibbs P, Horsman A. Peripheral enhancement and spatial contrast uptake heterogeneity of primary breast tumors: quantitative assessment with dynamic MRI. J Comput Assist Tomogr 1998; 22:35-46.
18. Degani H, Gusis V, Weinstein D, Fields S, Strano S. Mapping pathophysiological features of breast tumors by MRI at high spatial resolution. Nat Med 1997; 3:780-782.
19. Hoffmann U, Brix G, Knopp MV, Hess T, Lorenz WJ. Pharmacokinetic mapping of the breast: a new method for dynamic MR mammography. Magn Reson Med 1995; 33:506-514.
20. Boetes C, Barentsz JO, Mus RD, et al. MR characterization of suspicious breast lesions with a gadolinium-enhanced turbo-FLASH subtraction technique. Radiology 1994; 193:777-781.
21. Kuhl CK, Bieling H, Gieseke J, et al. Breast neoplasms: T2* susceptibility-contrast, first pass perfusion MR imaging. Radiology 1997; 202:87-95.
22. Kvistad KA, Lundgren S, FjØsne HE, Smenes E, Smethurst HB, Haraldseth O. Differentiating benign and malignant breast lesions with T2*-weighted first pass perfusion imaging. Acta Radiol 1999; 40: 45-51.
23. Helbich T, Roberts TPL, Gossmann A, et al. MR imaging of breast tumors: testing of different analytic methods with gadopentetate (abstr). Eur Radiol 1999; 9 (suppl 1):410.
24. Daniel BL, Yen YF, Glover GH, et al. Breast disease: dynamic spiral MR imaging. Radiology 1998; 209:499-509.
25. Metz CE. Some practical issues of experimental design and data analysis in radiological ROC studies. Invest Radiol 1989; 24:234-245.
26. Kuhl CK, Bieling HB, Giesek J, et al. Healthy premenopausal breast parenchyma in dynamic contrast-enhanced MR imaging of the breast: normal contrast medium enhancement and cyclical-phase dependency. Radiology 1997; 203: 137-144.
27. Griebel J, Mayr NA, de Vries A, et al. Assessment of tumor microcirculation: a new role of dynamic contrast MR imaging. J Magn Reson Imaging 1997; 7:111-119.
28. Rempp KA, Brix G, Wenz F, Becker CR, Gückel F, Lorenz WJ. Quantification of regional cerebral blood flow and volume with dynamic susceptibility contrast-enhanced MR imaging. Radiology 1994; 193:637-641.
29. Le Bihan D. Theoretical principles of perfusion imaging: application to magnetic resonance imaging. Invest Radiol 1992; 27:6-11.
30. Sorensen AG, Tievsky AL, Ostergaard L, Weisskoff RM, Rosen BR. Contrast agents in functional MR imaging. J Magn Reson Imaging 1997; 7:47-55.
31. Folkman J. Tumor angiogenesis. In: Mendelsohn J, Howley PM, Israel MA, et al, eds. The molecular basis of cancer. Philadelphia, Pa: Saunders, 1995; 206-232.
32. Less JR, Skalak TC, Sevick EM, Jain RK. Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. Cancer Res 1991; 51: 265-273.
33. Mühler A. Assessment of myocardial perfusion using contrast-enhanced MR imaging: current status and future developments. MAGMA 1995; 3:21-33.
34. Azavedo E, Svane G, Auer G. Stereotactic fine-needle biopsy in 2594 mammographically detected non-palpable lesions. Lancet 1989; 1:1033-1036.
35. Walters TK, Zuckerman J, Nisbet-Smith A, Hudson E, Chia Y, Burke M. Fine needle aspiration biopsy in the diagnosis and management of fibroadenoma of the breast. Br J Surg 1990; 77:1215-1217.
36. Fischer U, Kopka L, Grabbe E. Invasive mucinous carcinoma of the breast missed by contrast-enhanced MR imaging of the breast. Eur Radiol 1996; 6:929-931.
37. Stomper PC, Herman S, Klippenstein DL. Suspect breast lesions: findings at dynamic gadolinium-enhanced MR imaging correlated with mammographic and pathologic features. Radiology 1995; 197: 387-395.
38. Pochon S, Hyacinthe R, Terrettaz J, Robert F, Schneider M, Tournier H. Long circulating supermagnetic particles with high T2 relaxivity. Acta Radiol 1997; 38: 69-72.
39. Locopo N, Fanelli M, Gasparini G. Clinical significance of angiogenic factors in breast cancer. Breast Cancer Res Treat 1998; 52:159-173.